(Q37880146)

24 August 2017

1 reference

title

Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens (English)

1 reference

24 August 2017

0 references

Pechère JC

1

1 reference

24 August 2017

Gootz TD

series ordinal

2

1 reference

24 August 2017

publication date

1 June 1998

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

24 August 2017

published in

1 reference

24 August 2017

volume

17

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

405-412

1 reference

A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus

24 August 2017

cites work

1 reference

12 December 2020

Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model

1 reference

12 December 2020

In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia

1 reference

12 December 2020

In vitro activity of the new fluoroquinolone CP-99,219.

1 reference

12 December 2020

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin

1 reference

12 December 2020

The chemistry and biological profile of trovafloxacin

1 reference

12 December 2020

Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden

1 reference

12 December 2020

In vitro activity of trovafloxacin against Chlamydia pneumoniae

1 reference

12 December 2020

Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae

1 reference

12 December 2020

Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci

1 reference

12 December 2020

Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli

1 reference

12 December 2020

Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus

1 reference

12 December 2020

In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli

1 reference

12 December 2020

In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

1 reference

12 December 2020

In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates

1 reference

12 December 2020

In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis

1 reference

12 December 2020

In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest

1 reference

12 December 2020

Mechanisms of quinolone resistance

1 reference

12 December 2020

Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates

1 reference

12 December 2020

In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone

1 reference

12 December 2020

In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates

1 reference

12 December 2020

In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae

1 reference

12 December 2020

In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates

1 reference

12 December 2020

Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia

1 reference

12 December 2020

In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.

1 reference

12 December 2020

Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci

1 reference

12 December 2020

Mechanisms of Fluoroquinolone Resistance in Staphylococcus aureus

1 reference

12 December 2020

Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy

1 reference

12 December 2020

Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

1 reference

12 December 2020

In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens

1 reference

12 December 2020

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria

1 reference

12 December 2020

Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition

1 reference

12 December 2020

In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219) -letter-

1 reference

12 December 2020

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis

1 reference

12 December 2020

In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone

1 reference

12 December 2020

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

1 reference

12 December 2020

The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents

1 reference

12 December 2020

Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa.

1 reference

12 December 2020

Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects

1 reference

12 December 2020

Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods

1 reference

12 December 2020

Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones

1 reference

12 December 2020

The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria

1 reference

12 December 2020

In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.

1 reference

12 December 2020

Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria

1 reference

12 December 2020

Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates

1 reference

12 December 2020

Identifiers

DOI

10.1007/S100960050098

1 reference

24 August 2017

1 reference